BioSpace News Archive

Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced that the journal Advances in Therapy has published patient-perception data supporting clinical meaningfulness of overactive bladder symptom reduction for its FDA-approved OAB therapy, GEMTESA®, compared to placebo.

Avra, Inc. (OTC PINK: AVRN), is pleased to announce that it has closed the merger with Springs Rejuvenation, LLC (https://springsrejuvenation.com).

Novavax, Inc. announced that the World Health Organization has granted a second Emergency Use Listing for NVX-CoV2373, Novavax’ recombinant protein nanoparticle COVID-19 vaccine with Matrix-M™ adjuvant, for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

3D ICE improves standard of care for congenital heart disease and electrophysiology procedures by reducing need for general anesthesia, improving efficiency and expanding treatment options [20-December-2021] AURORA, Colo. , Dec. 20, 2021 /PRNewswire/ -- Children’s Hospital Colorado (Children’s Colorado ) is the first pediatric hospital in the world to use a 3D intrac

scPharmaceuticals Inc. announced that John Tucker, president & chief executive officer, will participate virtually in two upcoming investor conferences.

Orphan drugs are novel drugs which are dedicated to treat the disease conditions that are rare as well as life-threatening to small percentage of patient population at global level.

Opiant Pharmaceuticals, Inc. announced the Compensation Committee of the Company’s Board of Directors has approved the grant of restricted stock units covering an aggregate of 31,500 shares of common stock to six hired employees, pursuant to the Company’s 2021 Inducement Equity Incentive Plan.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), today announced that the company will present at two upcoming scientific meetings, the AACR Special Conference: Targeting RAS, being held January 7-10, 2022 in Lake Buena Vista, Florida and the ASCO GI Cancers Symposium, being held January 20-22 in San Francisco, California.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference.

Statera Biopharma (Nasdaq: STAB), announced today the enrollment and randomization of the first patient, with several more in screening for an initial study to evaluate STAT-205 as a potential treatment to mitigate SARS-CoV-2 progression, the virus that causes COVID-19.